All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2017; the latest 2023-10-25.
From the record
Dianthus Therapeutics, Inc.'s filings since 2017 show 3 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2023-02-02); an auditor change (8-K item 4.01, 2 times, the latest 2023-10-25) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
7 filed years; profitable in 0 of 10.
From the record
Dianthus Therapeutics, Inc.'s 7 filed years say what it did: it rose in 1 of 2 years; the deepest fall was 67% from fiscal 2024 to fiscal 2025; net income was positive in 0 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 1.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Dianthus Therapeutics, Inc.'s shareholder treatment is put at 1.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 12% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -33%: lost 33¢ per shareholder dollar. Leverage 7%: owes 7¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Dianthus Therapeutics, Inc. lost about 33 cents for every dollar of shareholders' money. Leverage: it owed about 7 cents per dollar of assets, and net share issuance: its share count grew 15.9% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 20% of 315 in its family; net margin -7973.3%.
From the record
Dianthus Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $2 million in fiscal 2025 ranks in the bottom 29% by size; a net margin of -7973.3% ranks in the bottom 12% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 6.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Dianthus Therapeutics, Inc.'s leadership is put at 6.7 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 33% of 415 in its family; the record of its people begins on 2023-09-12 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 3.2 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 43% of 273 in its family for room to expand.
From the record
Dianthus Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $51 million against no long-term debt tagged leaves 9.7% of its assets as net cash, bottom 26% of its family; cash from operations less capital spending is -6338.9% of revenue (bottom 10%); research spending of 7153.1% of revenue (top 8%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 42% of 306 in its family for growth drivers.
From the record
Dianthus Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew -67.4% (bottom 11%); research spending grew 70.5% a year (top 4%); capital spending grew -53.2% a year (bottom 18%) (its annual reports). Dianthus Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 9% of 233 in its family for expectations against reality.
From the record
Dianthus Therapeutics, Inc.'s newest year against its own record: net income of $162 million against a prior three-year average of $68 million (bottom 11%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 7%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made